Clinuvel Pharmaceuticals Ltd (ASX: CUV) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Clinuvel Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $608.24 million
P/E Ratio 16.89
Dividend Yield 0.42%
Shares Outstanding 50.06 million
Earnings per share 0.698
Dividend per share 0.05
Year To Date Return -26.00%
Earnings Yield 5.92%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Clinuvel Pharmaceuticals Ltd (ASX: CUV)
    Latest News

    Smiling elderly couple looking at their superannuation account, symbolising retirement.
    Share Gainers

    Why Clinuvel, SRG, Strike Energy, and Tietto shares are racing higher today

    these ASX shares are having a strong session on Thursday. But why?

    Read more »

    Stressed, unhappy and tired scientist with a headache working on a computer in a lab. Worried, anxious and frustrated pathologist, researcher and doctor struggling with burnout, tension and strain.
    Healthcare Shares

    Down 25% in a month, is this ASX 300 company about to sue the UK Government?

    What's going on at this healthcare share?

    Read more »

    A happy looking woman holding a colourful umbrella against a grey cloudy sky.
    Best Shares

    Top ASX shares to buy in July 2023

    Could these hand-picked shares be the portfolio boosters we need to ring in the new financial year?

    Read more »

    A scientist examining test results.
    Opinions

    Down 35% in a year, is the Imugene share price a buying opportunity right now?

    Is a 35% discount enticing enough to invest in this clinical-stage biotech. Here's my take.

    Read more »

    A young man sits at his desk working on his laptop with a big smile on his face due to his ASX shares going up and in particular the Computershare share price
    Opinions

    10 stocks for 10 years: How I would invest $10,000 in ASX shares right now

    I won't be conned into holding a huge stash of cash. Here are 10 investments I'd rather make for long…

    Read more »

    Businessman at the beach building a wall around his sandcastle, signifying protecting his business.
    Opinions

    3 defensive ASX shares surrounded by wide moats I'd buy with $5,000

    Investors can secure massive returns over the long term if a company holds a sustainable competitive advantage.

    Read more »

    A worried man holds his head and look at his computer.
    Share Fallers

    Why Clinuvel, Cogstate, Omni Bridgeway, and Westgold shares are sinking

    These ASX shares are ending the week in a disappointing fashion...

    Read more »

    Five people are leaping in the shallows of the beach water as sunset shines gold on them.
    52-Week Highs

    5 ASX 200 shares rocketing to new 52-week highs on Tuesday

    These stocks are making the most of the ASX 200's strong start to 2023.

    Read more »

    Arrows pointing upwards with a man pointing his finger at one.
    52-Week Highs

    4 ASX All Ordinaries shares hitting new 52-week highs today

    Do you know the coal and healthcare shares trading at 12-month highs?

    Read more »

    A couple are shocked and elated at the good news they've just seen on their devices.
    Share Gainers

    Why Clinuvel, Nitro, Premier Investments, and Pushpay shares are rising

    These ASX shares are on form on Monday...

    Read more »

    Top ten gold trophy.
    Share Market News

    Here are the top 10 ASX 200 shares today

    These ASX 200 shares posted the biggest gains on Wednesday.

    Read more »

    Man waves goodbye while looking at computer sitting at desk.
    Share Market News

    8 ASX 200 shares got kicked out of the index on Monday. How are they tracking?

    The S&P Dow Jones Indices quarterly rebalance saw eight shares depart the ASX 200 on Monday.

    Read more »

    Frequently Asked Questions

    Yes, Clinuvel Pharmaceuticals has historically paid one unfranked shareholder dividend a year.

    Clinuvel Pharmaceuticals generally pays its shareholder dividend in September.

    Clinuvel Pharmaceuticals does not have a dividend reinvestment plan.

    Clinuvel Pharmaceuticals Limited listed on the ASX on 13 February 2001.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    05 Sep 2024 $0.0500 100.00% Final 20 Sep 2024
    05 Sep 2023 $0.0500 100.00% Final 20 Sep 2023
    06 Sep 2022 $0.0400 100.00% Final 21 Sep 2022
    02 Sep 2021 $0.0250 0.00% Final 17 Sep 2021
    03 Sep 2020 $0.0250 0.00% Final 18 Sep 2020
    04 Sep 2019 $0.0250 0.00% Final 19 Sep 2019
    21 Sep 2018 $0.0200 0.00% Final 08 Oct 2018

    CUV ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Clinuvel Pharmaceuticals Ltd

    Clinuvel Pharmaceuticals Ltd (ASX: CUV) is an Australian-based global biopharmaceutical company developing drugs for the treatment of genetic and vascular disorders. Its principal product SCENESSE is a drug for an inherited disorder, erythropoietic protoporphyria, that causes an intolerance to light.

    Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to UV radiation and at repigmentation of the skin due to depigmentation disorders. Geographically, the company derives the majority of its revenue from its US and European markets.

     

    CUV Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    24 Dec 2024 $12.15 $0.04 0.33% 116,245 $12.05 $12.30 $12.02
    23 Dec 2024 $12.11 $0.32 2.71% 152,659 $11.79 $12.11 $11.73
    20 Dec 2024 $11.79 $-0.15 -1.26% 121,073 $12.00 $12.00 $11.72
    19 Dec 2024 $11.94 $-0.06 -0.50% 140,437 $11.87 $12.07 $11.76
    18 Dec 2024 $12.00 $-0.23 -1.88% 185,171 $12.25 $12.47 $11.96
    17 Dec 2024 $12.23 $0.08 0.66% 118,338 $12.17 $12.50 $12.17
    16 Dec 2024 $12.15 $0.02 0.16% 223,999 $12.10 $12.30 $11.85
    13 Dec 2024 $12.13 $-0.32 -2.57% 122,183 $12.42 $12.42 $12.12
    12 Dec 2024 $12.45 $-0.20 -1.58% 69,432 $12.65 $12.84 $12.43
    11 Dec 2024 $12.65 $-0.09 -0.71% 180,133 $12.70 $13.04 $12.64
    10 Dec 2024 $12.74 $0.33 2.66% 142,840 $12.30 $12.80 $12.19
    09 Dec 2024 $12.41 $-0.27 -2.13% 143,526 $12.66 $12.85 $12.32
    06 Dec 2024 $12.68 $-0.42 -3.21% 117,652 $13.00 $13.00 $12.63
    05 Dec 2024 $13.10 $0.14 1.08% 187,730 $12.90 $13.30 $12.90
    04 Dec 2024 $12.96 $0.00 0.00% 153,725 $12.90 $12.96 $12.56
    03 Dec 2024 $12.96 $-0.08 -0.61% 62,453 $12.97 $13.09 $12.87
    02 Dec 2024 $13.04 $-0.11 -0.84% 78,884 $13.23 $13.44 $12.95
    29 Nov 2024 $13.15 $0.06 0.46% 61,470 $13.10 $13.20 $12.97
    28 Nov 2024 $13.09 $0.05 0.38% 82,827 $13.09 $13.34 $12.95
    27 Nov 2024 $13.04 $-0.04 -0.31% 68,534 $13.08 $13.12 $12.90
    26 Nov 2024 $13.08 $0.17 1.32% 73,811 $12.95 $13.11 $12.87

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mrs Susan (Sue) Smith Non-Executive Director Sep 2019
    Mrs Smith manages an established consultancy business, providing advisory services to a range of healthcare organisations, investors, and boards of directors. She has led a career, serving for 14 years as Chief Executive Officer of The Princess Grace Hospital, London, and 11 years as the Chief Executive Officer of The Portland Hospital for Women and Children, London. Mrs Smith's specific expertise is in the implementation of operational strategies within complex and acute care environments, and in the interaction with healthcare authorities and UK regulators. Her most recent role was as the Chief Executive Officer of the Independent Doctors Federation, a membership organisation representing practising physicians within the UK independent healthcare sector.
    Dr Philippe J Wolgen Chief Executive OfficerManaging Director Dec 2005
    Dr Wolgen's leadership led to a long-term strategy for CLINUVEL. The product SCENESSE was reformulated, its medical application identified, European marketing authorisation was obtained in 2014 and systems were established to self-distribute the prescriptive product in the European Economic Area from June 2016. Dr Wolgen oversaw the submission of the scientific dossier to the US Food & Drug Administration (FDA) under a New Drug Application, which was approved in October 2019.
    Dr Karen Agersborg Non-Executive Director Jan 2018
    Dr Agersborg has diverse and practice experience in Pennsylvania and New Jersey, USA. She is Board Certified in both Internal Medicine and Endocrinology, Diabetes & Metabolism and holds specific expertise on the class of melanocortins. Her career has included inpatient, outpatient, and hospitalist positions across several prominent medical institutions. Dr Agersborg had career in managing commercial sales & distribution at Wyeth Pharmaceuticals (formerly Ayerst Laboratories).
    Dr Jeffrey Rosenfeld Non-Executive ChairmanNon-Executive Director Nov 2019
    Prof Rosenfeld is a neurosurgeon with experience in senior healthcare and medical research executive roles and career in the Australian Army. He is a retired Major General and a former Surgeon General, Australian Defence Force-Reserves. He has served on eight deployments to Rwanda, Iraq, Solomon Islands, Bougainville, and East Timor. He was the Founding Director of Monash University Institute of Medical Engineering (MIME)-Melbourne. He is developing a bionic vision device to restore vision in people without eyesight, and he is also an adviser in brain injury research. He is also member of the Risk Committee.
    Mr Matthew William Pringle Non-Executive Director Sep 2024
    Mr Pringle has experience in corporate finance, audit and assurance, governance and strategy, including over 25 years experience as a Partner at Pitcher Partners. His roles with Pitcher Partners included leading the corporate finance practice group, senior audit partner and leading the corporate governance and board advisory practice area.He is a director of Navalo Financial Services Group Limited, Hypersonix Launch Systems Limited, and the not-for-profit Anglicare Victoria.
    Dr Pearl E Grimes Non-Executive Director Sep 2024
    Dr Grimes is a dermatologist and a leading international authority on vitiligo and pigmentation disorders. She is the Founder and Director of the Vitiligo and Pigmentation Institute of Southern California where she treats patients from all over the world. Dr Grimes is also the director of the Grimes Institute for Medical and Aesthetic Dermatology, where she expertly treats a range of dermatologic health and aesthetic concerns in patients of all ethnicities and skin types. Dr Grimes also serves as a Clinical Professor of Dermatology at the David Geffen School of Medicine at UCLA and Chief Dermatologist for Versicolor Technologies.
    Mr Guy van Dievoet Non-Executive Director Sep 2024
    Mr van Dievoet has experience in investment banking, specialising in M&A. In this capacity he has worked for financial institutions, including the Merchant bank of IndoSuez in Belgium, ABN-AMRO, Bank BNP Group, and as executive-director for MeesPierson. Over the years he has provided strategic support on corporate growth, structuring and buy-build approaches, and assisted companies listing on the Brussels and Amsterdam Stock Exchanges (EuroNext).
    Ms Claire Newstead-Sinclair Company Secretary Aug 2024
    -
    Darren Keamy CFO & Company Secretary
    -
    Peter Vaughan Chief Financial Officer
    -
    Lachlan Hay Chief Operations Officer
    -
    Dennis Wright Chief Scientific Officer
    -
    Claire Newstead-Sinclair Company Secretary
    -
    Linda Teng Director of North American Operations
    -
    Emilie Rodenburger Director Global Clinical Affairs
    -
    Malcolm Bull Head of Australian Operations and Investor Relations
    -
    Azza Hamila Head of Quality Assurance and Drug Safety
    -
    Rose Quadbeck-Diel Snr VP Regulatory Affairs
    -
    Antonella Colucci VP Commercial Affairs
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Ltd 10,225,972 20.42%
    BNP Paribas Nominees Pty Ltd ACF (Clearstream) 5,685,193 11.35%
    BNP Paribas Nominees Pty Ltd 4,988,645 9.96%
    J P Morgan Nominees Australia Pty Limited 3,629,550 7.25%
    Dr Philippe Jacques Wolgen 3,425,222 6.84%
    Citicorp Nominees Pty Limited 3,416,310 6.82%
    Ender 1 LLC 2,590,824 5.17%
    BNP Paribas Nominees Pty Ltd (IB AU Noms Retail Client) 2,207,904 4.41%
    HSBC Custody Nominees (Australia) Ltd A/C2 922,480 1.84%
    Emilino Group Pty Ltd (Emilino Super Fund) 601,447 1.20%
    National Nominees Limited 548,778 1.10%
    Mr Darren Michael Keamy 362,890 0.72%
    Dr Mark Edwin Badcock 346,772 0.69%
    Mr David William Trevorrow 229,600 0.46%
    BNP Paribas Nominees Pty Ltd (Agency Lending A/C) 229,044 0.46%
    Dr Dennis Wright 188,812 0.38%
    Mr David John Lewis 185,000 0.38%
    Mr Trent Sheldon Redding 177,370 0.35%
    Rusty Hammer Pty Ltd (Archipelago Holdings SF A/C) 150,722 0.30%
    Mr Simon John Bown 146,000 0.29%

    Profile

    since

    Note